An Italian-led study published earlier this year reported that androgen deprivation therapy may play a protective role against the risk of SARS-CoV-2 infection. Using an expansive enterprise-wide COVID-19 testing registry, Cleveland Clinic researchers set out to validate this report. Eric Klein, MD, discusses their findings.
Cleveland Clinic has begun enrolling patients in a prospective, national clinical study designed to evaluate the use of a multi-cancer early detection test, which has demonstrated the ability to detect more than 50 cancers through a single blood draw.
Findings from a new study show that time-to-treatment, at least in the short term, is not significantly associated with adverse outcomes in patients with high-risk prostate cancer. Eric Klein, MD, Chair of the Glickman Urological and Kidney Institute and a co-author of the study, comments on the implications of these findings.
A new study examines the rate of downgrading in patients with high-grade prostate cancer on initial biopsy. Eric Klein, MD, Chair of Glickman Urological & Kidney Institute and co-author of the study, comments on the investigation and shares clinical insights.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Cleveland Clinic is now offering the IsoPSA™ test, a novel prostate-specific antigen assay, for patients with a PSA > 4ng/ml who are facing a decision on prostate biopsy.
AUA will host a virtual experience on June 27-28 with a full line-up of keynote lectures, clinical guidelines, semi-live surgeries and late-breaking science. Be sure to check out four cant-miss sessions featuring five Cleveland Clinic urologists.
A prototype blood-based screening test evaluated by Cleveland Clinic researchers and others can accurately detect and localize multiple types of cancer, often before symptoms show. The promising results raise hopes that the assay will help achieve the long-sought goal of population-scale early detection of cancer.
PD-L2 plays a significant part in prostate cancer immune modulation and could be a worthwhile prognostic biomarker as well as an immune checkpoint inhibition target, according to a large genetic analysis.
The IsoPSA prostate-specific antigen test could reduce unnecessary prostate biopsies by more than 40% while reliably differentiating among high-grade, low-grade and benign disease, a new validation study has found.
The paradigm for prostate cancer screening with PSA continues to evolve, as do complementary testing tools. Here’s one take from a longtime urologist.